Not the way I see it. They have to pay the bills somehow until the revenue flows in...in the near future. They have big interest payments, lots of key personnel to pay, lots of R&D to pay.
Yes, big biotech companies take a boatload of cash to get off the ground, but they've been working at it for years and are mere weeks/months from finally turning the corner, and yet they still don't have an over-bloated share structure. Amazing!
How sweet! A genuine biotech play with lot patents at the their disposal, many more filed for, numerous medical markets that they can target without years of FDA clinical trials, and many of those markets could prove to have very high profit margins as well!
News 
Market Data 
Discover 
